MedTrace Logo

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

NCT04000555 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-04-21

No results posted yet for this study

Summary

The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices.

Conditions

  • Clostridium Difficile Infection
  • Clostridium Difficile Infection Recurrence

Interventions

DRUG

Oral Vancomycin

Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics

OTHER

Placebo

Matched placebo twice a day prescribed for the duration of antibiotics

Sponsors & Collaborators

  • University of South Florida

    lead OTHER

Principal Investigators

  • Mindy Sampson, DO · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2022-06-11
Completion
2022-06-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04000555 on ClinicalTrials.gov